F W Thielen
Overview
Explore the profile of F W Thielen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heine R, Thielen F, Mathijssen R, van Leeuwen R, Franken M, Uyl-de Groot C
PLoS One
. 2024 Feb;
19(2):e0293264.
PMID: 38300937
Background: Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems. Cost-based pricing models are discussed as a possibility for cost containment....
2.
Bakker L, Thielen F, Redekop W, Groot C, Blommestein H
BMC Med Res Methodol
. 2023 May;
23(1):132.
PMID: 37248477
Background: In economic evaluations, survival is often extrapolated to smooth out the Kaplan-Meier estimate and because the available data (e.g., from randomized controlled trials) are often right censored. Validation of...
3.
Oosten L, Chamuleau M, Thielen F, de Wreede L, Siemes C, Doorduijn J, et al.
Ann Hematol
. 2017 Dec;
97(2):255-266.
PMID: 29209924
Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational...
4.
Thielen F, Van Mastrigt G, Burgers L, Bramer W, Majoie H, Evers S, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2016 Nov;
16(6):705-721.
PMID: 27805466
This article is part of the series "How to prepare a systematic review of economic evaluations (EES) for informing evidence-based healthcare decisions", in which a five-step approach is proposed. Areas...